AIMS/HYPOTHESIS: We investigated the long-term impact of diabetic ketoacidosis (DKA) at onset on metabolic regulation and residual beta cell function in a Danish population with type 1 diabetes. METHODS: The study is based on data from DanDiabKids, a Danish national diabetes register for children. The register provides clinical and biochemical data on patients with type 1 diabetes diagnosed in 1996-2009 and then followed-up until 1 January 2012. Repeated-measurement models were used as statistical methods. RESULTS: The study population comprised 2,964 children <18 years. The prevalence of DKA at diagnosis was 17.9%. Of the total subjects, 8.3% had mild, 7.9% had moderate and 1.7% had severe DKA. DKA (moderate and severe) was associated with increased HbA1c (%) levels (0.24; 95% CI 0.11, 0.36; p = 0.0003) and increased insulin dose-adjusted HbA1c (IDAA1c, 0.51; 95% CI 0.31, 0.70; p < 0.0001) during follow-up, after adjustment for covariates. Children without a family history of diabetes were more likely to present with DKA (19.2% vs 8.8%, p < 0.0001); however, these children had a lower HbA1c (%) level over time (-0.35; 95% CI -0.46, -0.24; p < 0.0001). Continuous subcutaneous insulin infusion (CSII) was associated with a long-term reduction in HbA1c, changing the effect of DKA, after adjustment for covariates (p < 0.0001). CONCLUSIONS/ INTERPRETATION: DKA at diagnosis was associated with poor long-term metabolic regulation and residual beta cell function as assessed by HbA1c and IDAA1c, respectively; however, CSII treatment was associated with improvement in glycaemic regulation and residual beta cell function, changing the effect of DKA at onset in our population.
AIMS/HYPOTHESIS: We investigated the long-term impact of diabetic ketoacidosis (DKA) at onset on metabolic regulation and residual beta cell function in a Danish population with type 1 diabetes. METHODS: The study is based on data from DanDiabKids, a Danish national diabetes register for children. The register provides clinical and biochemical data on patients with type 1 diabetes diagnosed in 1996-2009 and then followed-up until 1 January 2012. Repeated-measurement models were used as statistical methods. RESULTS: The study population comprised 2,964 children <18 years. The prevalence of DKA at diagnosis was 17.9%. Of the total subjects, 8.3% had mild, 7.9% had moderate and 1.7% had severe DKA. DKA (moderate and severe) was associated with increased HbA1c (%) levels (0.24; 95% CI 0.11, 0.36; p = 0.0003) and increased insulin dose-adjusted HbA1c (IDAA1c, 0.51; 95% CI 0.31, 0.70; p < 0.0001) during follow-up, after adjustment for covariates. Children without a family history of diabetes were more likely to present with DKA (19.2% vs 8.8%, p < 0.0001); however, these children had a lower HbA1c (%) level over time (-0.35; 95% CI -0.46, -0.24; p < 0.0001). Continuous subcutaneous insulin infusion (CSII) was associated with a long-term reduction in HbA1c, changing the effect of DKA, after adjustment for covariates (p < 0.0001). CONCLUSIONS/ INTERPRETATION: DKA at diagnosis was associated with poor long-term metabolic regulation and residual beta cell function as assessed by HbA1c and IDAA1c, respectively; however, CSII treatment was associated with improvement in glycaemic regulation and residual beta cell function, changing the effect of DKA at onset in our population.
Authors: B Karges; A Neu; S E Hofer; J Rosenbauer; W Kiess; H Rütschle; A Dost; H Kentrup; R W Holl Journal: Klin Padiatr Date: 2011-01-26 Impact factor: 1.349
Authors: M Fernandez Castañer; E Montaña; I Camps; J Biarnes; J F Merino; J M Escriba; V Nacher; P Rosel; J Soler Journal: Diabetes Metab Date: 1996-10 Impact factor: 6.041
Authors: N Glaser; P Barnett; I McCaslin; D Nelson; J Trainor; J Louie; F Kaufman; K Quayle; M Roback; R Malley; N Kuppermann Journal: N Engl J Med Date: 2001-01-25 Impact factor: 91.245
Authors: Melanie Rodacki; Joana Rodrigues Dantas Pereira; Aline Moreira Nabuco de Oliveira; Bianca Barone; Renata Mac Dowell; Paula Perricelli; Michelle Telles Bravo; Marcus Miranda de Oliveira; Julia Dias Brum; Luciana Camara Belem; Phelipe Guimarães de Ornellas; Renata Szundy Berardo; Jorge Luescher; Ludmila Campos; Andrea de Menezes Vangelotti; Rosane Kupfer; Lenita Zajdenverg; Adolpho Milech; Jose Egidio Paulo de Oliveira Journal: Diabetes Res Clin Pract Date: 2007-05-02 Impact factor: 5.602
Authors: Young-Jun Seo; Chang Dae Kum; Jung Gi Rho; Young Suk Shim; Hae Sang Lee; Jin Soon Hwang Journal: Ann Pediatr Endocrinol Metab Date: 2022-01-25
Authors: Laura M Jacobsen; Kendra Vehik; Riitta Veijola; Katharina Warncke; Jorma Toppari; Andrea K Steck; Patricia Gesualdo; Beena Akolkar; Markus Lundgren; William A Hagopian; Jin-Xiong She; Marian Rewers; Anette-G Ziegler; Jeffrey P Krischer; Helena Elding Larsson; Michael J Haller Journal: Diabetes Care Date: 2022-03-01 Impact factor: 17.152
Authors: Marcos M Lima-Martínez; Ernesto Guerra-Alcalá; Miguel Contreras; José Nastasi; Janelle A Noble; Constantin Polychronakos Journal: Endocrinol Diabetes Metab Case Rep Date: 2014-09-01
Authors: Arleta Rewers; Nathan Kuppermann; Michael J Stoner; Aris Garro; Jonathan E Bennett; Kimberly S Quayle; Jeffrey E Schunk; Sage R Myers; Julie K McManemy; Lise E Nigrovic; Jennifer L Trainor; Leah Tzimenatos; Maria Y Kwok; Kathleen M Brown; Cody S Olsen; T Charles Casper; Simona Ghetti; Nicole S Glaser Journal: Diabetes Care Date: 2021-06-29 Impact factor: 17.152